

Mitsunobu Doi\* and  
Akiko AsanoOsaka University of Pharmaceutical Sciences,  
4-20-1 Nasahara, Takatsuki, Osaka 569-1094,  
Japan

Correspondence e-mail: doi@gly.oups.ac.jp

## Key indicators

Single-crystal X-ray study

T = 100 K

Mean  $\sigma(\text{C}-\text{C}) = 0.003 \text{ \AA}$ 

R factor = 0.049

wR factor = 0.111

Data-to-parameter ratio = 19.5

For details of how these key indicators were  
automatically derived from the article, see  
<http://journals.iucr.org/e>.Montanastatin,  $\text{cyclo}[-(\text{Val-D-Hyv-D-Val-Lac})_2-]$ 

Crystals of montanastatin anhydride,  $\text{C}_{36}\text{H}_{60}\text{N}_4\text{O}_{12}$ , were grown from a hexylene glycol solution. A crystallographic twofold axis runs through the centre of the molecule. The aliphatic side chains located on one side of the peptide ring form a hydrophobic region. The shape of the whole molecule is rectangular and is similar to the structure of the valinomycin analogue, *viz.*  $\text{cyclo}[-(\text{D-Val-L-Hyv-L-Val-D-Hyv})_2-]$ .


Received 19 July 2002

Accepted 23 July 2002

Online 31 July 2002

## Comment

Montanastatin has been isolated from a Montana soil actinomycete, *Streptomyces anulatus*, as a cancer-cell-growth inhibitory cyclooctadepsipeptide (Pettit *et al.*, 1999). This peptide contains  $\alpha$ -hydroxyisovaleric acid (Hyv) and lactic acid (Lac), and is composed of two repeating units of tetrapeptide, Val-D-Hyv-D-Val-Lac. Such a repeated sequence is similar to that in valinomycin, which has three repeating units. Montanastatin gives some solvated crystals (refcode KAHMAH in the Cambridge Structural Database; Allen & Kennard, 1993). An anhydrous form, (I), was obtained from hexylene glycol solution, and its structure is reported here.



A crystallographic twofold axis is located in the montanastatin molecule; the asymmetric unit is thus one half molecule. The backbone shape is a rectangular ring (Fig. 1*a*). The Lac residues shift from the peptide ring (Fig. 1*b*) making a small loop with an intramolecular hydrogen bond between D-Val<sup>3</sup> and Lac<sup>4</sup>: N<sub>3</sub>...O<sub>4</sub> (Table 1). The aliphatic side chains of Val<sup>1</sup>, D-Hyv<sup>2</sup> and D-Val<sup>3</sup> are located on one side of the peptide ring (Fig. 1*b*), forming a hydrophobic region. Only the methyl groups of Lac residues are located on the other side. In this structure, the chiral sequence of (L-D-D-L) is important for creating a hydrophobic region. However, the relative positions of the side chains are different from those of valinomycin (Duax *et al.*, 1972; Karle, 1975). The conformational characteristics of montanastatin are similar to those of a valinomycin analogue,  $\text{cyclo}[-\text{D-Val-L-Hyv-L-Val-D-Hyv})_2-]$  (Grochulski *et al.*, 1992).

## Experimental

Hyv was synthesized according to a previously reported method (Gisin *et al.*, 1969), and montanastatin was synthesized by a conventional liquid-phase method. Montanastatin (20 mg) was dissolved in 0.2–0.3 ml hexylene glycol, and crystals grew after about 30 d at room temperature. A crystal was mounted on a nylon loop (Hampton Research Inc., USA) with glycerol and was flash-frozen under a nitrogen stream at 100 K.

### Crystal data

$C_{36}H_{60}N_4O_{12}$   
 $M_r = 740.88$   
 Orthorhombic,  $C222_1$   
 $a = 13.488$  (6) Å  
 $b = 17.868$  (7) Å  
 $c = 16.452$  (7) Å  
 $V = 3965$  (3) Å<sup>3</sup>  
 $Z = 4$   
 $D_x = 1.241$  Mg m<sup>-3</sup>

Mo  $K\alpha$  radiation  
 Cell parameters from 3994 reflections  
 $\theta = 2.3$ – $28.0^\circ$   
 $\mu = 0.09$  mm<sup>-1</sup>  
 $T = 100$  (2) K  
 Block, colourless  
 $0.32 \times 0.24 \times 0.20$  mm

### Data collection

Bruker SMART APEX CCD diffractometer  
 $\omega$  scans  
 Absorption correction: multi-scan (SADABS; Sheldrick, 1996)  
 $T_{\min} = 0.854$ ,  $T_{\max} = 0.982$   
 13003 measured reflections

4717 independent reflections  
 4545 reflections with  $I > 2\sigma(I)$   
 $R_{\text{int}} = 0.031$   
 $\theta_{\max} = 28.6^\circ$   
 $h = -17 \rightarrow 17$   
 $k = -15 \rightarrow 23$   
 $l = -22 \rightarrow 22$

### Refinement

Refinement on  $F^2$   
 $R[F^2 > 2\sigma(F^2)] = 0.049$   
 $wR(F^2) = 0.111$   
 $S = 1.18$   
 4717 reflections  
 242 parameters  
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0472P)^2 + 1.956P]$   
 where  $P = (F_o^2 + 2F_c^2)/3$   
 $(\Delta/\sigma)_{\max} < 0.001$   
 $\Delta\rho_{\max} = 0.32$  e Å<sup>-3</sup>  
 $\Delta\rho_{\min} = -0.22$  e Å<sup>-3</sup>  
 Absolute structure: (Flack, 1983),  
 1912 Friedel pairs  
 Flack parameter = 0.1 (9)

**Table 1**

Hydrogen-bonding geometry (Å, °).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$N_1-H5_1\cdots O_2^i$	0.880	2.037	2.901 (2)	167.1
$N_3-H22_3\cdots O_4^{ii}$	0.880	2.363	3.037 (2)	133.6


Symmetry codes: (i)  $\frac{1}{2} + x, \frac{3}{2} - y, 2 - z$ ; (ii)  $1 - x, y, \frac{3}{2} - z$ .

The structure of montanastatin is consistent with the absolute configurations of the amino acids and carboxylic acids, Val, D-Val, D-Hyv and Lac, although the Flack test results are meaningless.

Data collection: *SMART* (Bruker, 1998); cell refinement: *SMART*; data reduction: *SAINT-Plus* (Bruker, 1998); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *PLATON* (Spek, 2001); software used to prepare material for publication: *PARST* (Nardelli, 1995).

## References

Allen, F. H. & Kennard, O. (1993). *Chem. Des. Autom. News*, **8**, 1, 31–37.  
 Bruker (1998). *SAINT-Plus* (Version 5) and *SMART* (Version 5). Bruker AXS Inc., Madison, Wisconsin, USA.



**Figure 1**

The structure of montanastatin (*PLATON*; Spek, 2001). Top (a) and side (b) views of the depsipeptide ring are shown. Dashed lines represent hydrogen bonds.

Duax, W. L., Hauptman, H., Weeks, C. M. & Norton, D. A. (1972). *Science*, **176**, 911–914.  
 Flack, H. D. (1983). *Acta Cryst.* **A39**, 876–881.  
 Gisin, B. F., Merrifield, R. B. & Tosteson, D. C. (1969). *J. Am. Chem. Soc.* **91**, 2691–2695.  
 Grochulski, P., Smith, G. D., Langs, D. A., Duax, W. L., Pletnev, V. Z. & Ivanov, V. T. (1992). *Biopolymers*, **32**, 757–764.  
 Karle, I. L. (1975). *J. Am. Chem. Soc.* **97**, 4379–4386.  
 Nardelli, M. (1995). *J. Appl. Cryst.* **28**, 659.  
 Pettit, G. R., Tan, R., Melody, N., Kielty, J. M., Pettit, R. K., Herald, D. L., Tucker, B. E., Mallavia, L. P., Doubek, D. L. & Schmidt, J. M. (1999). *Bioorg. Med. Chem.* **7**, 895–899.  
 Sheldrick, G. M. (1996). *SADABS*. University of Göttingen, Germany.  
 Sheldrick, G. M. (1997). *SHELXL97* and *SHELXS97*. University of Göttingen, Germany.  
 Spek, A. L. (2001). *PLATON*. Utrecht University, The Netherlands.